arrow
A

Andrea Wang-Gillam

Barnes-Jewish Hospital
H指数:48
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer

合成长肽和DNA个性化癌症疫苗在胰腺癌中诱导强烈的neoantigen特异性T细胞反应

2026-01-010
OA
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

glecirasib在KRAS G12C突变实体瘤中的有效性和安全性:两项I/II期试验的合并分析

2025-10-020
OAAI
Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma

肿瘤内细胞邻域协调胰腺导管腺癌的结果

2024-06-014
PRE
Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer

联合kras-mapk通路抑制剂和HER2-directed药物偶联物对胰腺癌有效

2024-03-204
OAAI
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Science
IF45.8
2024-01-010
OA
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
2023-10-315
OAAI
MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial
2023-01-018
PRE
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

德法替尼、派姆单抗和吉西他滨治疗晚期难治性胰腺癌患者: I期剂量递增和扩展研究

2022-10-1349
OA
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers
2021-12-1553
OA
Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial
2021-09-0126
PREAI
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment

536患者来源的异种移植模型的综合表征优先考虑靶向治疗的候选者

2021-08-2466
OAAI
A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study
2020-08-159
PRE